Healthcare-associated infections (HAIs) have become a pressing concern for both healthcare providers and economies across Europe. Annually, HAIs lead to 16 million additional hospitalization days, resulting in a staggering cost of 7 billion €. These infections are often caused by antibiotic-resistant bacteria, posing a significant global health threat. Airborne particles, acting as carriers for pathogens, have a strong correlation with the presence of molds and bacteria, making effective infection control a critical priority.
In the face of this challenge, Genano's innovative technology offers a comprehensive solution to combat contamination from multi-resistant bacteria, addressing the imminent threat of antibiotic resistance. Recent clinical studies have demonstrated the remarkable effectiveness of Genano's air treatment systems in critical hospital areas, leading to significant improvements in air quality and infection control.
Study 1: Enhancing Air Quality in Endoscopy Rooms
A controlled study conducted in a Western European Hospital revealed that Genano devices placed in Endoscopy rooms achieved an impressive 80% reduction in particle concentration per cubic meter within just 24 hours. The Genano® 5250 system not only improved air quality but also elevated the ISO class from ISO7 to ISO6, indicating a healthier environment. Furthermore, it successfully reduced other bioaerosol contamination by eliminating microbial loads carried by particles. Healthcare personnel noticed a perceptible improvement in air quality.
Researchers recommend combining Genano's air treatment system with periodic bio-decontamination, such as the 35% HPV system, for optimal results.
Study 2: Reducing Surgical Site Infections (SSI)
A scientific clinical study demonstrated a remarkable 54% decrease in surgical site infections (SSI) with the implementation of Genano technology. It not only improved air quality in operating rooms according to strict ISO standards but also created an overall healthier air environment. This reduction in SSI not only decreases human suffering but also offers substantial cost-saving opportunities for hospitals.
Read more: https://www.genano.com/references/537-decrease-in-surgical-site-infections-with-genano
Validation through NHS Scotland's Testing
Genano's effectiveness was further validated through NHS Scotland's testing. The Genano devices reduced total viable counts (TVC) levels in the air by an impressive 62%. Additionally, mold levels in the air decreased by an average of 82%. These results highlight the success of Genano's filtration product in consistently reducing airborne microbial levels, thus lowering the risk of airborne disease transmission, including threats like COVID-19. Notably, both clinical staff and patients accepted these devices well.
Conclusion
Genano's Complete Bioaerosol Control technology has emerged as a groundbreaking solution for infection control in hospitals. Its ability to reduce particle concentration, improve air quality, and decrease the risk of HAIs and SSI demonstrates its crucial role in enhancing patient safety and reducing healthcare costs. In the face of rising antibiotic resistance and the threat of infectious diseases, Genano offers a beacon of hope for hospitals striving to provide a safer and healthier environment for their patients and staff.
Link to Infection Control White Paper
.png)